Eyepoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Royal Bank Of Canada

Royal Bank Of Canada assumed coverage on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a report released on Tuesday, MarketBeat Ratings reports. The firm issued an outperform rating and a $28.00 price target on the stock.

Several other research analysts have also recently commented on the company. Wall Street Zen upgraded Eyepoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. Mizuho cut their price target on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday, May 16th. Chardan Capital cut their price target on Eyepoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Thursday, May 29th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.67.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT opened at $8.92 on Tuesday. Eyepoint Pharmaceuticals has a 12 month low of $3.91 and a 12 month high of $13.99. The stock’s 50-day moving average is $6.89 and its two-hundred day moving average is $6.93. The stock has a market cap of $613.79 million, a PE ratio of -3.70 and a beta of 1.61.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, hitting the consensus estimate of ($0.65). Eyepoint Pharmaceuticals had a negative return on equity of 54.27% and a negative net margin of 261.91%. The business had revenue of $24.50 million for the quarter, compared to analysts’ expectations of $8.84 million. On average, research analysts anticipate that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Summit Investment Advisors Inc. raised its stake in Eyepoint Pharmaceuticals by 39.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company’s stock valued at $51,000 after buying an additional 1,940 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Eyepoint Pharmaceuticals during the fourth quarter valued at approximately $59,000. Virtus ETF Advisers LLC acquired a new stake in Eyepoint Pharmaceuticals during the fourth quarter valued at approximately $67,000. AlphaQuest LLC raised its stake in Eyepoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock valued at $73,000 after buying an additional 9,670 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Eyepoint Pharmaceuticals during the fourth quarter valued at approximately $76,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.